CLINICAL TRIAL: HUPERZINE A TRIAL

临床试验：石杉碱甲试验

• 批准号: 7724997
• 负责人: RUTH MULNARD MCCARGAR
• 金额: $ 0.23万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-12-01 至 2008-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7724997
• 关键词: Aging; Alzheimer' s Disease; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Dose; Funding; Grant; Institutes; Institution; Patients; Phase II Clinical Trials; Placebos; Population; Randomized; Research; Research Personnel; Resources; Safety; Source; United States National Institutes of Health; Week; cognitive function; huperzine A

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a Phase II clinical trial supported by the National Institute on Aging and Marco Hi-Tech for a twenty-four week period of exposure in which patients with Alzheimer's disease are randomized to receive escalating doses of Huperzine A versus placebo to evaluate the safety, tolerability, and impact on cognitive function of this agent in this population.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 这是一项由国家老龄化研究所和 Marco Hi-Tech 支持的 II 期临床试验，为期 24 周，阿尔茨海默氏病患者随机接受递增剂量的石杉碱甲与安慰剂，以评估安全性。耐受性以及该药物对该人群认知功能的影响。